Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Galectin Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.89M. For fiscal 2025 it was -$23.88M. The highest annual figure on record is -$3.10M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.88M | – |
| FY2024 | Dec 31, 2024 | -$41.77M | – |
| FY2023 | Dec 31, 2023 | -$32.97M | – |
| FY2022 | Dec 31, 2022 | -$31.06M | – |
| FY2021 | Dec 31, 2021 | -$24.31M | – |
| FY2020 | Dec 31, 2020 | -$20.60M | – |
| FY2019 | Dec 31, 2019 | -$10.85M | – |
| FY2018 | Dec 31, 2018 | -$10.18M | – |
| FY2017 | Dec 31, 2017 | -$15.89M | – |
| FY2016 | Dec 31, 2016 | -$16.41M | – |
| FY2015 | Dec 31, 2015 | -$16.98M | – |
| FY2014 | Dec 31, 2014 | -$12.43M | – |
| FY2013 | Dec 31, 2013 | -$7.48M | – |
| FY2012 | Dec 31, 2012 | -$7.50M | – |
| FY2011 | Dec 31, 2011 | -$5.68M | – |
| FY2010 | Dec 31, 2010 | -$3.10M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.11M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.00M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.98M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.21M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.58M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.52M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.12M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.86M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.87M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.44M | – |
See a number that looks wrong?